Soleno Therapeutics Inc
SLNODelisted May 18, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001484565
Soleno Therapeutics Inc was delisted on May 18, 2026; its insiders filed their last Form 4 on May 18, 2026; 230 institutions reported holding it in 13F filings for Q1 2026, worth $2.09B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:16 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 27, 2025 | Mar 7, 2024 | Mar 21, 2023 | Mar 28, 2022 |
| Revenue | $190.4M | – | – | – | – |
| Cost of revenue | $2.70M | – | – | – | – |
| Operating expenses | $181.0M | $187.7M | $41.4M | $24.4M | $31.5M |
| Research and development | $40.6M | $78.6M | $25.2M | $15.3M | $21.5M |
| Selling, general and administrative | $132.1M | $105.9M | $13.5M | $9.84M | $10.8M |
| Operating income | $9.41M | -$187.7M | -$41.4M | -$24.4M | -$31.5M |
| Interest expense | $5.48M | – | – | – | – |
| Income tax | $0 | – | – | – | – |
| Net income | $20.9M | -$175.8M | -$39.0M | -$24.1M | -$30.9M |
| EPS, basic | $0.40 | $-4.38 | $-2.36 | $-2.87 | – |
| EPS, diluted | $0.39 | $-4.38 | $-2.36 | $-2.87 | – |
| Weighted shares, basic | 50.8M | 40.2M | 16.5M | 8.40M | – |
| Weighted shares, diluted | 52.4M | 40.2M | 16.5M | 8.40M | – |
| Margins and growth | |||||
| Operating margin | 4.9% | – | – | – | – |
| Net margin | 11.0% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 27, 2025 | Mar 7, 2024 | Mar 21, 2023 | Mar 28, 2022 |
| Cash and equivalents | $70.1M | $87.9M | $169.7M | $14.6M | $21.3M |
| Short-term investments | $235.4M | $203.5M | – | – | – |
| Accounts receivable | $28.2M | – | – | – | – |
| Inventory | $15.0M | – | – | – | – |
| Total current assets | $355.8M | $293.9M | $171.4M | $15.6M | $22.4M |
| Property, plant and equipment | $185.0K | $186.0K | $12.0K | $26.0K | $33.0K |
| Intangible assets | $4.86M | $6.80M | $8.75M | $10.7M | $12.6M |
| Total assets | $563.8M | $331.0M | $180.7M | $26.5M | $35.6M |
| Accounts payable | $12.4M | $8.88M | $3.15M | $1.78M | $3.25M |
| Total current liabilities | $61.4M | $18.7M | $11.5M | $7.31M | $8.01M |
| Long-term debt | $49.9M | $49.8M | – | – | – |
| Total liabilities | $113.7M | $85.9M | $23.2M | $16.1M | $17.8M |
| Shareholders' equity | $450.1M | $245.1M | $157.5M | $10.3M | $17.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 27, 2025 | Mar 7, 2024 | Mar 21, 2023 | Mar 28, 2022 |
| Operating cash flow | $46.8M | -$69.1M | -$24.9M | -$20.8M | -$27.8M |
| Capital expenditures | $73.0K | $218.0K | $0 | $13.0K | $22.0K |
| Free cash flow | $46.7M | -$69.3M | -$24.9M | -$20.8M | -$27.8M |
| Depreciation and amortization | $2.02M | $1.99M | $1.96M | $1.96M | $1.96M |
| Stock-based compensation | $45.8M | $100.0M | $5.95M | $2.53M | $3.28M |
| Share buybacks | $100.1M | – | – | – | – |
| Investing cash flow | -$201.8M | -$225.7M | $0 | -$13.0K | -$22.0K |
| Financing cash flow | $137.2M | $213.0M | $180.0M | $14.1M | -$128.0K |
| Net change in cash | -$17.8M | -$81.8M | $155.1M | -$6.70M | -$27.9M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 24.1% | – | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 30, 2026 | 52.1M | +3.4% | SEC |
| Apr 29, 2026 | 52.1M | +3.4% | SEC |
| Feb 19, 2026 | 51.6M | +12.6% | SEC |
| Oct 31, 2025 | 53.7M | +24.6% | SEC |
| Aug 1, 2025 | 53.1M | +36.7% | SEC |
| May 2, 2025 | 50.4M | +50.8% | SEC |
| Feb 26, 2025 | 45.9M | +41.3% | SEC |
| Oct 31, 2024 | 43.1M | +41.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q3 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.